Context
How does CBD compare to other supplements for arthritis?
TL;DR — What the Evidence Shows
Several supplements have been studied for osteoarthritis. Curcumin has the most promising results so far.
Glucosamine has been studied the most, but strong evidence shows it does not work. CBD has fewer arthritis trials than most supplements listed here.
How does the evidence compare?
This table compares supplements that have been tested in randomized controlled trials for osteoarthritis. No head-to-head trial has ever compared CBD directly to any other supplement. All comparisons are indirect. Evidence certainty follows the GRADE framework.
| Supplement | Arthritis trials | Evidence | Key findings | Monthly cost |
|---|---|---|---|---|
| Glucosamine / chondroitin | 40+ | High Certainty | High certainty that it does not work. The largest trial (GAIT, n=1,583) found no significant difference from placebo (Clegg 2006). Effect disappears in high-quality trials. ACR 2019 and OARSI both strongly recommend against it. | $15–$40 |
| Curcumin (turmeric extract) | 15–20 | Low Certainty | Largest effect sizes of any supplement in this list. Non-inferior to ibuprofen in one trial (n=367) (Kuptniratsaikul 2014). But trials are small and short. Fundamental bioavailability problem: the body absorbs very little curcumin. Highly bioavailable formulations linked to liver injury (NCCIH warning, April 2025). | $15–$45 |
| Omega-3 fatty acids (fish oil) | 9–15 | Low Certainty | Small effect on pain. Below the threshold for a moderate effect. The largest long-term trial (1,398 participants, 5.3 years) was negative (Deng 2023). More relevant for inflammatory arthritis than osteoarthritis. ACR 2019 strongly recommends against for osteoarthritis. | $10–$30 |
| SAMe (S-adenosylmethionine) | <10 | Very Low Certainty | Not different from placebo in Cochrane analysis (Rutjes 2022). Pain improved about 2 points on a 0–10 scale in both SAMe and placebo groups. Too few participants to draw conclusions. Cochrane: "Routine use should not be recommended." | $30–$60 |
| Collagen (hydrolyzed and UC-II) | ~35 | Moderate Certainty | Moderate certainty for function improvement. Low certainty for pain (Liang 2024). Trial sequential analysis confirmed sufficient evidence for function but not definitively for pain. One 2025 randomized controlled trial of combined UC-II + hydrolyzed collagen found no benefit over placebo. | $20–$50 |
| Topical capsaicin | 8 | Low Certainty | About 1 out of 8 patients achieves meaningful benefit beyond placebo. But about 1 out of 3 cannot tolerate the burning sensation (Ho 2024). The only supplement with a positive ACR recommendation (conditional). OARSI recommends against it. | $10–$25 |
| CBD (oral) | 3 | Very Low Certainty | No benefit over placebo. Vela 2022 (Vela 2022): difference of 0.23 points on a 100-point pain scale — essentially zero. Bialas 2023 (Bialas 2023) and CANOA 2025 (Mojoli 2025): no significant difference on any outcome. Across all pain types, 15 of 16 CBD trials were negative (Moore 2024). | $38–$150+ |
Evidence certainty follows GRADE methodology. Monthly costs are typical US OTC supplement prices. All comparisons are indirect—no head-to-head trials exist. (Kolasinski 2020)
How much research exists for each supplement?
CBD has the smallest evidence base of any supplement in this comparison. To put it in perspective:
- Glucosamine has been tested in more than 40 osteoarthritis-specific randomized controlled trials. The largest enrolled 1,583 participants.
- Curcumin has been tested in 15 to 20 osteoarthritis trials. The largest enrolled 367 participants.
- Collagen has been tested in about 35 osteoarthritis trials with over 3,000 total participants.
- CBD has been tested in 3 osteoarthritis-specific randomized controlled trials. The largest enrolled 136 participants.
This does not mean CBD cannot work. It means we know less about it than about other supplements. The trials that do exist have consistently found no benefit over placebo.
Do all supplements share the same regulation problem?
Yes. Every supplement in this table shares the same FDA oversight gap. The key facts:
- Supplements are not tested for effectiveness before they are sold. The FDA regulates drugs before they reach the market, but supplements are regulated after the fact.
- Manufacturers can make "structure/function" claims (e.g., "supports joint health") without proving the claim is true.
- Quality varies widely. Independent testing regularly finds products that do not contain what the label claims.
- CBD has an additional legal complication: the FDA has stated that CBD cannot legally be sold as a dietary supplement, yet it is widely sold as one.
This regulation gap applies to glucosamine, curcumin, collagen, and every other supplement, not just CBD. More on CBD product quality problems.
CBD interacts with many common medications
- Blood thinners (warfarin): CBD can increase bleeding risk by raising INR levels
- Statins, blood pressure medications, and immunosuppressants may also be affected
- CBD inhibits the same liver enzymes that process many prescription drugs
Based on cited sources. This is not personalized medical advice — discuss with your healthcare provider.
Full drug interaction guide, medication checker, and pharmacist discussion checklist.
Key sources cited on this page
Page last reviewed: March 2026 · Authored by Claude (Anthropic AI) · Research methodology